Vineet Jindal | VP, Corporate Communications & Strategy |
Colin Meyer | Chief Medical Officer & EVP, Product Development |
Manmeet Soni | CFO & EVP |
Warren Huff | Chairman, CEO & President |
Yigal Nochomovitz | Citigroup |
Maurice Raycroft | Jefferies |
Adam Walsh | Stifel, Nicolaus & Company |
Joseph Schwartz | SVB Leerink |
Jack Allen | Robert W. Baird & Co. |
Matthew Kaplan | Ladenburg Thalmann & Co. |
Ladies and gentlemen, thank you for standing by, and welcome to the Reata Pharmaceuticals first quarter financial results and update on development programs conference call. [Operator Instructions].
Before the company proceeds with its remarks, please note the forward-looking statement disclosure in the company's press release. The company will be making forward-looking statements on today's call. There are many factors that could cause results to differ from expectations, including those noted in the company's SEC filings.